Oncology specialists should inform patients about a risk of serious toxicity related to dihydropyrimidine dehydrogenase (DPD) deficiency and should test for DPYD variants before starting treatment ...
Immunotherapy. 2012;4(9):939-945. The percentage of patients achieving complete clearance of their AKs in the 5-FU group was 19, 28.2 and 52.6% in the 1-, 2- and 4-week treatment groups, respectively.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results